Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 35, Issue 6, 2001, Pages 437-452

  Lissbrant, Ingela Franck ^a,b   Lissbrant, Erik ^a   Damber, Jan Erik ^b   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Blood flow; Endothelial cell; Proliferation; Prostate; Regulation of prostate growth; VEGF

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CANSTATIN; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; METALLOPROTEINASE INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; PROLACTIN 16; PROTEIN TYROSINE KINASE INHIBITOR; RESTIN; ROQUINIMEX; SURAMIN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASOSTATIN;

ANGIOGENESIS; BLOOD FLOW; BLOOD VESSEL; CANCER GROWTH; CAPILLARY DENSITY; CARCINOMA IN SITU; CASTRATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE MARKER; DRUG TARGETING; GENE THERAPY; GROWTH REGULATION; HORMONAL REGULATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; REGULATORY MECHANISM; REVIEW; STROMA CELL; TUMOR VASCULARIZATION;

HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0035691274     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655901753367532     Document Type: Review

References (185)

1. Transient ischemia induces apoptosis in the ventral prostate of the rat
2. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration
3. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats
4. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence
5. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity
6. Early effects of castration on the vascular system of the rat ventral prostate gland
7. Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival
8. The effects of androgen deprivation on the prostate gland: Cell death mediated by vascular regression
9. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland
10. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
11. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
12. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging
13. Vascular endothelial growth factor expression and tumor angio-genesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
14. Angiogenesis in urological malignancy
15. Advances in angiogenesis research: Relevance to urological oncology
16. Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target
17. Microvessel density in prostate cancer: Prognostic and therapeutic utility
18. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
19. Tumor angiogenesis: Past, present and the near future
20. Anticancer drug targets: Approaching angiogenesis
21. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
22. Why angiogenesis inhibition?
23. Tumor angiogenesis
24. Development and differentiation of endothelium
25. Mechanisms of angiogenesis and arterio-genesis
26. Circulating endothelial precursors: Mystery, reality, and promise
27. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
28. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
29. Angiogenesis: New insights and therapeutic potential
30. Mechanisms of angiogenesis
31. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
32. VPF/VEGF and the angiogenic response
33. Blood vessel maturation: Vascular development comes of age
34. Angiogenesis and angiogenesis inhibition: An overview
35. Angiogenesis in cancer, vascular, rheumatoid and other disease
36. Lymphangiogenesis and tumor metastasis: Myth or reality?
37. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
38. Switch to the angiogenic phenotype during tumorigenesis
39. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
40. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
41. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
42. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
43. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
44. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
45. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
46. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
47. Antiangiogenic therapy
48. New perspectives in clinical oncology from angiogenesis research
49. Assessment of tumor vascularization: Immunohisto-chemical and non-invasive methods
50. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
51. Tumour suppressor genes and angiogenesis: The role of TP53 in fibroblasts
52. Role of vascular endothelial growth factor in the regulation of angiogenesis
53. Molecular and biological properties of vascular endothelial growth factor
54. Factors promoting tumor angiogenesis
55. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
56. Increased vascularization in mice overexpressing angiopoietin-1
57. Importance of angiogenesis in reproductive physiology
58. Manipulating angiogenesis. From basic science to the bedside
59. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice
60. Defective angiogenesis in mice lacking endoglin
61. Tumor angiogenesis and endothelial cell modulatory factors
62. Angiogenesis: New aspects relating to its initiation and control
63. Angiogenesis: A dynamic balance of stimulators and inhibitors
64. The rationale and future potential of angiogenesis inhibitors in neoplasia
65. Anti-angiogenic treatment of human cancer: Pitfalls and promises
66. Angiostatin induces and sustains dormancy of human primary tumors in mice
67. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
68. Tumoral vacularity: What does it tell us about the growth and spread of cancer
69. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
70. Tumoral vascularity as a prognostic factor in cancer
71. Tumor angiogenesis: Review of current applications in tumor prognostication
72. Is determination of angiogenic activity in human tumours clinically useful?
73. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: Correlation with Gleason's score, microvessel density, and epithelial cell proliferation
74. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma
75. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
76. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis
77. Clinical significance of spontaneous apoptosis in advanced gastric adenocarcinoma
78. Angiogenic factors as tumor markers
79. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
80. In vivo monitoring of tumor angiogenesis with MR imaging
81. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis
82. Is angiogenesis inhibition the Holy Grail of cancer therapy?
83. New strategies in anti-vascular cancer therapy
84. Antiangiogenic tumour therapy: Will it work?
85. Microvascularity in benign prostatic hyperplasia
86. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia
87. Expression of the VEGF-receptor Flt-1 in benign, premalignant, and malignant prostate tissues
88. Prostatic Intra-epithelial Neoplasia Qualitative and quantitative analyses of the blood capillary architecture on this tissue sections
89. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
90. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer
91. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients
92. Analysis of the capillary architecture in the precursors of prostate cancer: Recent findings and new concepts
93. PIN I-III: When should we interfere?
94. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer
95. VEGF is required for growth and survival in neonatal mice
96. Cyclic angiogenesis and blood vessel regression in the ovary: Blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion
97. Involution of the sheep mammary gland
98. Ultrastructure of blood vessel regression in involution of foreign-body granuloma
99. Cell death by apoptosis during involution of the lactating breast in mice and rats
100. Regulation of apoptosis in the prostate gland by androgenic steroids
101. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death
102. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death
103. Androgen receptor localization in different cell types of the adult rat prostate
104. Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs
105. Immuno-histochemical localization of the androgen receptor in rat and human tissues
106. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta- hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry
107. Dynamic contrast enhanced MR1 of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA
108. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor
109. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration
110. Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration
111. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens
112. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
113. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
114. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate
115. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts
116. Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications
117. Expression of vascular endothelial growth factor receptors in human prostate cancer
118. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
119. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells
120. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine- differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting
121. Vascular endothelial growth factor content in metastasizing and non-metastasizing dunning prostatic adenocarcinoma
122. Angiogenically active vascular endothelial growth Ke factor is over- expressed in malignant human and rat prostate carcinoma cells
123. Relative expression of type IV collagenae, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers
124. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
125. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
126. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
127. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
128. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer
129. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth
130. Role of interleukin 10 and transforming growth factor betal in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice
131. Transforming growth factor betal is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
132. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions
133. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer
134. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
135. Prostate stroma: Physiology
136. Correlation between neo-vascularisation and neuroendocrine differentiation in prostatic carcinoma
137. Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival
138. Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression
139. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
140. Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators
141. A strategy to discover circulating angiogenesis inhibitors generated by human tumors
142. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: Potential role of host-tumor interaction
143. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
144. Independent association of angiogenesis index with outcome in prostate cancer
145. The application of an antiangiogenic gene (thrombos pondin-1) in the treatment of human prostate cancer xenografts
146. Antiangiogenic activity of prostate-specific antigen
147. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
148. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
149. Immunohisto-chemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer
150. Tumour angiogenesis in latent prostatic carcinoma
151. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
152. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
153. An analysis of microvessel density, androgen receptor, p53 and HER- 2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications
154. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31
155. Independent prognostic importance of microvessel density in clinically localized prostate cancer
156. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma
157. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis
158. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
159. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
160. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
161. Vascular integrin alpha(v)-beta3: A new prognostic indicator in breast cancer
162. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
163. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
164. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy
165. Comparison of microvascularization in diagnostic needle biopsies and radical prostatectomies in prostate carcinoma
166. Microvessel density in core biopsies of prostatic adenocarcinoma: A stage predictor?
167. Color Doppler imaging in predicting the biologic behavior of prostate cancer: Correlation with disease-free survival
168. Serum vascular endothelial growth factor is often elevated in disseminated cancer
169. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
170. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
171. Angiogenic peptides in prostatic disease
172. Vascular endothelial growth factor in prostate cancer
173. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study
174. Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis
175. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
176. Elevated levels of angiogenic cytokines in the plasma of cancer patients
177. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials
178. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
179. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
180. The logic of anti-angiogenic gene therapy
181. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
182. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy
183. Androgen deprivation and radiation therapy: Sequencing studies using the Shionogi in vivo tumor system
184. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer